Suppr超能文献

血浆中的外泌体miR-2276-5p是胶质瘤潜在的诊断和预后生物标志物。

Exosomal miR-2276-5p in Plasma Is a Potential Diagnostic and Prognostic Biomarker in Glioma.

作者信息

Sun Jingxian, Sun Zhenying, Gareev Ilgiz, Yan Tao, Chen Xin, Ahmad Aamir, Zhang Daming, Zhao Boxian, Beylerli Ozal, Yang Guang, Zhao Shiguang

机构信息

Department of Neurosurgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.

Institute of Brain Science, Harbin Medical University, Harbin, China.

出版信息

Front Cell Dev Biol. 2021 Jun 1;9:671202. doi: 10.3389/fcell.2021.671202. eCollection 2021.

Abstract

INTRODUCTION

Exosomal microRNAs (miRNAs) play an essential role in near and distant intercellular communication and are potential diagnostic and prognostic biomarkers for various cancers. This study focused on evaluation of exosomal miR-2276-5p in plasma as a diagnostic and prognostic biomarker for glioma.

METHODS

Plasma exosomes from 124 patients with glioma and 36 non-tumor controls were collected and subjected to quantitative real-time polymerase chain reaction (qRT-PCR) analysis for the exosomal miR-2276-5p expression. Bioinformatic analyses were performed to identify a gene target, and CGGA and TCGA databases were checked for evaluation of prognostic relevance.

RESULTS

The exosomal miR-2276-5p in glioma patients had a significantly decreased expression, compared with non-glioma patients ( < 0.01). Receiver operating characteristics (ROC) curve analyses were observed to regulate the diagnostic sensitivity and specificity of miR-2276-5p in glioma; the area under the curve (AUC) for miR-2276-5p was 0.8107. The lower expression of exosomal miR-2276-5p in patients with glioma correlated with poorer survival rates. RAB13 was identified as the target of miR-2276-5p which was high in glioma patients, especially those with higher tumor grades and correlated with poor survival.

CONCLUSION

The circulating exosomal miR-2276-5p is significantly reduced in the plasma of glioma patients, and thus, it could be a potential biomarker for patients with glioma for diagnostic and/or prognostic purposes.

摘要

引言

外泌体微小RNA(miRNA)在近程和远程细胞间通讯中发挥着重要作用,是多种癌症潜在的诊断和预后生物标志物。本研究聚焦于评估血浆中外泌体miR-2276-5p作为胶质瘤的诊断和预后生物标志物。

方法

收集124例胶质瘤患者和36例非肿瘤对照者的血浆外泌体,进行定量实时聚合酶链反应(qRT-PCR)分析外泌体miR-2276-5p的表达。进行生物信息学分析以鉴定基因靶点,并检查CGGA和TCGA数据库以评估预后相关性。

结果

与非胶质瘤患者相比,胶质瘤患者血浆外泌体miR-2276-5p表达显著降低(<0.01)。观察到通过受试者工作特征(ROC)曲线分析来调节miR-2276-5p在胶质瘤中的诊断敏感性和特异性;miR-2276-5p的曲线下面积(AUC)为0.8107。胶质瘤患者中外泌体miR-2276-5p的低表达与较差的生存率相关。RAB13被鉴定为miR-2276-5p的靶点,其在胶质瘤患者中高表达,尤其是肿瘤分级较高的患者,且与不良生存相关。

结论

胶质瘤患者血浆中循环外泌体miR-2276-5p显著降低,因此,它可能是胶质瘤患者用于诊断和/或预后目的的潜在生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/02db/8204016/3ad7b16a22d7/fcell-09-671202-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验